TETRA 5th Workshop: Advancing Biophotonics and Biomaterials Successfully Concluded

The TETRA COST Action (CA23125) successfully concluded its 5th Workshop on Biophotonics and Biomaterials, held on 13–14 July 2026 at the Trinity Conference Centre, Dublin, Ireland, as a pre-conference workshop of META 2026. The event brought together leading researchers from Europe and beyond to explore the latest advances in biophotonics, biomaterials, metamaterials, and their applications in cancer diagnosis and biomedical imaging.

TETRA COST Action Showcases Next-Generation Biomedical Technologies at META 2026

DUBLIN, IRELAND – Continuing its mission to transform cancer recognition through innovative metamaterial-based technologies, the TETRA COST Action (CA23125) successfully organized its 5th Workshop on Biophotonics and Biomaterials on 13–14 July 2026 at the Trinity Conference Centre in Dublin.

Exploring the Future of Biomedical Diagnostics

The two-day scientific program featured internationally recognized speakers presenting cutting-edge research on cancer diagnostics, biomedical imaging, biophotonics, novel metamaterials, plasmonics, implantable sensors, Raman spectroscopy, quantum photonics, and photothermal cancer therapy. Discussions highlighted how advanced electromagnetic and photonic technologies are accelerating the translation of laboratory discoveries into practical clinical solutions.

Strengthening International Scientific Collaboration

Researchers from universities and research institutions across Europe, the United States, and Israel exchanged ideas, established new collaborations, and identified future research directions within the TETRA network. Interactive sessions, networking activities, and strategic discussions reinforced the Action’s interdisciplinary approach to developing next-generation diagnostic technologies.

By bringing together experts in engineering, physics, materials science, and biomedical research, the 5th TETRA Workshop further strengthened the international collaboration essential for developing innovative, non-invasive diagnostic tools and advancing the future of precision medicine.